Skip to content

Author

Abdulaziz Kamili

We have 2 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma – the BELI(E)VE trial

The BELI(E)VE trial aims to establish a novel personalized therapeutic approach for a specific subset of MM patients by combining belantamab mafodotin and venetoclax, potentially inducing deep and durable remissions in t(11;14)-positive RRMM patients.

C. Schaefers, Cyrus Khandanpour, M. Hänel et al. · 0 citations
Open access Aug 2026

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience.

Deeper pre-infusion response was associated with significantly lower toxicity after BCMA-directed CAR-T therapy, identifying pre-infusion disease control as a potentially modifiable determinant of toxicity.

J. Artzenroth, R. Kosch, Maximilian Al-Bazaz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.